Monoclonal anti-CD52 antibodies: a potential mode of therapy for parvovirus B(19) hepatitis

Transplant Proc. 2001 May;33(3):2151-3. doi: 10.1016/s0041-1345(01)01955-8.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Alanine Transaminase / blood
  • Alemtuzumab
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm
  • Antigens, CD / immunology
  • Antigens, Neoplasm*
  • Aspartate Aminotransferases / blood
  • Bone Marrow Transplantation
  • CD52 Antigen
  • Child
  • Female
  • Follow-Up Studies
  • Glycoproteins / immunology
  • Hepatitis, Viral, Human / drug therapy*
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Liver Function Tests
  • Male
  • Parvoviridae Infections / drug therapy*
  • Parvovirus B19, Human*
  • Time Factors

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm
  • Antigens, CD
  • Antigens, Neoplasm
  • CD52 Antigen
  • CD52 protein, human
  • Glycoproteins
  • Immunosuppressive Agents
  • Alemtuzumab
  • Aspartate Aminotransferases
  • Alanine Transaminase